Table 1 Patient, tumor, and surgical therapy characteristics of all female cases with primary, non-metastatic, unilateral breast cancer diagnosed at the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012
Total cases (n = 4102) | Number of cases | Percent (%) |
|---|---|---|
Patient characteristics | ||
Age at diagnosis in years (n = 4102) | ||
median | 57 years | |
< 51 | 1355 | 33.0 |
51–65 | 1638 | 39.9 |
> 65 | 1109 | 27.0 |
total | 4102 | 100.0 |
Menopausal status (n = 4102) | ||
pre | 1377 | 33.6 |
peri | 130 | 3.2 |
post | 2498 | 60.9 |
missing | 97 | 2.4 |
total | 4102 | 100.0 |
Affected breast (n = 4102) | ||
left | 2066 | 50.4 |
right | 2036 | 49.6 |
total | 4102 | 100.0 |
Tumor characteristics | ||
Main tumor histology (n = 4102) | ||
In-situ Carcinoma | 499 | 12.2 |
Invasive Carcinoma | 3603 | 87.8 |
Invasive ductal carcinoma (no specific type) | 3082 | 85.5 |
Invasive lobular carcinoma | 481 | 13.3 |
other (e.g. invasive medullar/mixed) | 40 | 1.1 |
total | 4102 | 100.0 |
T stage for invasive cases with adjuvant therapy (n = 2997) | ||
pT1 | 1863 | 62.2 |
pT1a | 161 | |
pT1b | 486 | |
pT1c | 1202 | |
pTmic | 7 | |
unknown | 7 | |
pT2 | 909 | 30.3 |
pT3 | 138 | 4.6 |
pT4 | 58 | 1.9 |
pTx/missing | 29 | 1.0 |
total | 2997 | 100.0 |
T stage for invasive cases with neoadjuvant therapy (n = 606) | ||
ypT0 | 168 | 27.7 |
ypTis | 16 | 2.6 |
ypT1 | 224 | 37.0 |
ypT1a | 47 | |
ypT1b | 52 | |
ypT1c | 115 | |
ypTmic | 8 | |
unknown | 2 | |
ypT2 | 127 | 21.0 |
ypT3 | 47 | 7.8 |
ypT4 | 16 | 2.6 |
ypTx/missing | 8 | 1.3 |
total | 606 | 100.0 |
N stage for invasive cases (n = 3603) | ||
pN0 | 2473 | 68.6 |
pN1 | 655 | 18.2 |
pN2 | 243 | 6.7 |
pN3 | 158 | 4.4 |
pNx/missing | 74 | 2.1 |
total | 3603 | 100.0 |
Grading (invasive cases, n = 3603) | ||
Grade 1 | 600 | 16.7 |
Grade 2 | 1924 | 53.4 |
Grade 3 | 962 | 26.7 |
missing | 117 | 3.2 |
total | 3603 | 100.0 |
Estrogen receptor (invasive cases, n = 3603) | ||
positive | 2877 | 79.9 |
negative | 585 | 16.2 |
missing | 141 | 3.9 |
total | 3603 | 100.0 |
Progesterone receptor (invasive cases, n = 3603) | ||
positive | 2599 | 72.1 |
negative | 859 | 23.8 |
missing | 145 | 4.0 |
total | 3603 | 100.0 |
HER2 receptor (invasive cases, n = 3603) | ||
positive | 346 | 9.6 |
negative | 3118 | 86.5 |
missing | 139 | 3.9 |
total | 3603 | 100.0 |
Ki-67 status (invasive cases, n = 3603) | ||
< 14 % | 1463 | 40.6 |
≥ 14 % | 1541 | 42.8 |
missing | 599 | 16.6 |
total | 3603 | 100.0 |
Surgical therapy characteristics | ||
Surgical therapy (n = 4102) | ||
Breast Conserving Surgery | 2999 | 73.1 |
Mastectomy | 1103 | 26.9 |
total | 4102 | 100.0 |
Axillary staging (n = 4102) | ||
SLND only | 1671 | 40.7 |
SLND + ALND | 501 | 12.2 |
ALND only | 1600 | 39.0 |
none | 330 | 8.1 |
total | 4102 | 100.0 |